Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding

Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function

(2017) Inmaculada Hernandez et al.   THROMBOSIS RESEARCH

Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients

(2016) Elaine Nguyen et al.   PHARMACOTHERAPY

Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease

(2016) Steen Husted et al.   THROMBOSIS AND HAEMOSTASIS

Outcomes in a Warfarin-Treated Population With Atrial Fibrillation

(2016) Fredrik Björck et al.   JAMA Cardiology

Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF–TIMI 48 trial

(2015) Elizabeth A. Magnuson et al.   AMERICAN HEART JOURNAL

Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry

(2015) Sean D. Pokorney et al.   AMERICAN HEART JOURNAL

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study

(2014) Torben Bjerregaard Larsen et al.   AMERICAN JOURNAL OF MEDICINE

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

(2014) Craig T. January et al.   CIRCULATION

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

(2014) Craig T. January et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control

(2014) Andrej Janzic et al.   PHARMACOECONOMICS

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin

(2014) T. Lanitis et al.   JOURNAL OF MEDICAL ECONOMICS

Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation

(2013) William J. Canestaro et al.  

Novel Oral Anticoagulants Versus Warfarin Therapy at Various Levels of Anticoagulation Control in Atrial Fibrillation—A Cost-Effectiveness Analysis

(2013) Joyce H. S. You   JOURNAL OF GENERAL INTERNAL MEDICINE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

(2013) Amanda R. Harrington et al.   STROKE

Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation

(2013) Doug Coyle et al.   VALUE IN HEALTH

Identifying Potential Predictors of High-Quality Oral Anticoagulation Assessed by Time in Therapeutic International Normalized Ratio Range: A Prospective, Long-Term, Single-Center, Observational Study

(2012) Gustavo Lamego de Barros Costa et al.   CLINICAL THERAPEUTICS

Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention

(2011) Stephanie R. Earnshaw et al.   ARCHIVES OF INTERNAL MEDICINE

Catalogue of EQ-5D Scores for the United Kingdom

(2011) Patrick W. Sullivan et al.   MEDICAL DECISION MAKING

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

(2010) Ron Pisters et al.   CHEST

What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?

(2009) R Scott Braithwaite et al.   MEDICAL CARE

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation

(2008) Yi Wan et al.